O Tratamento do Câncer com Interleucina-2
DOI:
https://doi.org/10.32635/2176-9745.RBC.1985v31n4.3367Palavras-chave:
Imunoterapia, Interleucina-2, Neoplasias/terapiaResumo
Artigo de opinião de Vivian Rumjaneck, do Instituto Nacional de Câncer (INCA), sobre imunoterapia como forma de tratamento contra o câncer, com lnterleucina-2.
Downloads
Referências
Grimm EA, et al: Lymphokine - activated killer cell phenomenon. Lysis of natural killer — resistent fresh solid tumor cells by interleukín 2 — activated autologous human peripheral blood lymphocytes. J. exp. Med. 1982; 155; 1823-1841. DOI: https://doi.org/10.1084/jem.155.6.1823
Rayner AA, et al: Lymphokine — activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer 1985; 55: 1327-1333. DOI: https://doi.org/10.1002/1097-0142(19850315)55:6<1327::AID-CNCR2820550628>3.0.CO;2-O
Bubenfk I, et al: Growth inhibition of an MC — induced mouse sarcoma by TCGF (IL-2) — Containing preparations. Câncer Immunol. Immunother. 1983; 14: 205-206. DOI: https://doi.org/10.1007/BF00205362
Donohue IH, et al: In vivo administration of purified jurkad derived interleukin 2 in mice. Cancer res. 1984; 44; 1380-1386.
Rosemberg SA, et al: Regression of established pulmonar metastases and subcutaneoustumor mediated by the systemic administration of high dose recombinant IL2. J. exp. Med. 1985; 161: 1169-118ª DOI: https://doi.org/10.1084/jem.161.5.1169
Bridon C, et al: Clearance rates and systemic effects of intravenousiy administered interleukin-2 (IL-2) containing preparations in human subjects. Brit. J. Cancer 1983; 47: 123-133. DOI: https://doi.org/10.1038/bjc.1983.15
Lotze MT, et al: In vivo administration of purified interleukin 2. I-Half life and immunologic effects of the jurkad cell line derived IL2. J. Immunol. 1985; 134:157-166. DOI: https://doi.org/10.4049/jimmunol.134.1.157
Lotze MT, et al; In vivo administration of purified interleukin 2. II — Half life, immunologic infects, andexpansion of peripheral lymphoid cells in vivo with recombined IL-2. J. Immunol. 1985; 135: 2865-2875. DOI: https://doi.org/10.4049/jimmunol.135.4.2865
Castro-Faria H, et al: Immunochemotherapy of established mouse tumors. 5th International Congress of immunology Tokyo-Japan. 1983.
EItinghausen SE, et al: Recombined interleukin 2 stimulated in vivo proliferation of adoptively Transferred lymphokene —activated killer (LAK) cells. J. Immunol. 1985; 135: 3623-3635. DOI: https://doi.org/10.4049/jimmunol.135.5.3623
Cheever MA,etal; Angmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J. exp. Med. 1982; 155: 968-980. DOI: https://doi.org/10.1084/jem.155.4.968
Cheever MA, et al: Potential for specific cancer therapy with immune T lymphocytes. J. Biol. Response mod. 1984; 3; 113-127.
Mulé II, et al: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant lnterleukin-2. Science 1984; 225: 1487-1489. DOI: https://doi.org/10.1126/science.6332379
Lafreniére R and Rosemberg LA; Adoptive immunotherapy of murine hepatic metástases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and non immunogenic sarcomas and an adenocarcinoma. J. Immunol. 1985; 135: 4273-4280. DOI: https://doi.org/10.4049/jimmunol.135.6.4273
Rosemberg SA, et al; Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant lnterleukin-2 to patients with metastatic cancer. New Eng. J. Med. 1985; 313: 1485-1492. DOI: https://doi.org/10.1056/NEJM198512053132327
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
